

#Events
B cells
p < 0.01
T cells
p < 0.05
CD8+ T cells
p < 0.05
CD4+ T cells
p < 0.05
CD4 Naive
p < 0.01
SRC-3+/+
SRC-3-/-

FIG. 1

FIG. 2A



Probe intensity
1200
1000
800
600
400
200
0
1422737_at
1448027_at
Non-Lactating Mammary Gland
Lactating Mammary Gland
Prostate
Myeloid Progenitor
Granulocytes
CD8+ T cells
CD4+ T cells
Foxp3+ Tregs

FIG. 2B



Pearson's Correlation with Foxp3 in Tregs
0.5
0.4
0.3
0.2
0.1
0
-0.1
-0.2
-0.3
-0.4
Tregs
0.5
0.4
0.3
BCL3
NCOA3
MED15
ANP32A
CARM1
ASXL1
SPEN
STAT3
NCOA1

FIG. 3A



shLuc
shSRC-3
Relative mRNA expression
0.0
0.5
1.0
SRC-3
FOXP3
CD25
CTLA-4
PD-1

FIG. 3B



FoxP3 promoter activity (RLU)
0
2000
4000
6000
8000
10000
12000
0
125
250
375
pSG5-SRC-3 (ng)

FIG. 4A




FIG. 4B

FIG. 4C




FIG. 5




SRC3F/F Control Mice
Treg cell-specific SRC-3 KO mice
(FoxP3-Cre-ERT2;SRC-3F/F)
Tamoxifen
treatment
(5 Days)
5 days
Treg cell
Isolation
Adoptive Cell Transfer
Retro-orbital injection of Tregs
E0771 Tumor Bearing C57BL/6

FIG. 6

FIG. 7A


Before Adopt. Transfer
1000
800
600
400
200
Tumor Bearing C57BL/6J
SRC-3 KO Treg
Cont Treg
NO AT
Days After AT
1
4
9
13
17
20
23
28
50000
40000
30000
20000
10000



Tumor Luciferase Activity
14
12
10
8
6
4
2
0
-2
0
5
10
15
20
25
30
Days after Adoptive Transfer
WT cells-AT-Controls
Control SRC-3+ Tregs
SRC-3-KO Tregs
Tumor Elimination
No breast cancer tumor at >150 days (disease-free survival)

FIG. 7B